Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000535040 | SCV000642908 | likely benign | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2024-01-10 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000727817 | SCV000855239 | uncertain significance | not provided | 2018-09-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000727817 | SCV001780306 | likely benign | not provided | 2020-10-08 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001844195 | SCV002104044 | likely benign | not specified | 2022-02-07 | criteria provided, single submitter | clinical testing | Variant summary: TTN c.23899T>C alters a non-conserved nucleotide resulting in a synonymous change. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 2e-05 in 248202 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.23899T>C in individuals affected with Dilated Cardiomyopathy/Limb Girle Muscular Dystrophy/TTN-related disorders and no experimental evidence demonstrating its impact on protein function have been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (Likely Benign, n=2, VUS, n=1). Based on the evidence outlined above, the variant was classified as likely benign. |